ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0905

Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis

Philip Mease1, Arthur Kavanaugh2, Alexis Ogdie3, Alvin Wells4, Martin Bergman5, Dafna Gladman6, Frank Behrens7, Sven Richter8, Michele Brunori9, Lichen Teng8, Benoit Guerette8 and Josef Smolen10, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2UC San Diego Health System, San Diego, CA, 3Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4Aurora Rheumatology and Immunotherapy Center, Franklin, 5Drexel University College of Medicine, Philadelphia, PA, 6Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 7CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 8Amgen Inc., Thousand Oaks, 9Amgen Europe GmbH, Rotkreuz, Switzerland, 10Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Meeting: ACR Convergence 2020

Keywords: Disease Activity, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Apremilast (APR) is associated with comparable ACR response rates in DMARD-naive vs DMARD-experienced patients (pts) with PsA (Wells AF, et al. Rheumatology. 2018;57:1253-63; Kavanaugh A, et al. Arthritis Res Ther. 2019;21:118). A question that remains is if DMARD-naive pts treated with APR have greater chances of achieving treatment targets than DMARD-experienced pts. cDAPSA is a commonly used treatment target. We assessed the predictive value of baseline (BL) clinical disease status on achieving long-term cDAPSA treatment targets at Week 52 among DMARD-naive subjects in PALACE 4; compared these findings vs those recently reported from PALACE 1-3 in subjects with prior exposure to DMARDs; and provided further evidence that at a group level, achievement of cDAPSA disease targets with APR is associated with no or mild articular and extra-articular disease activity by Week 52.

Methods: This post hoc analysis included subjects assigned to APR 30 mg BID at BL who had available cDAPSA data at BL. We calculated the probabilities of shifting across different cDAPSA categories (remission [REM]: ≤4; low disease activity [LDA]: >4 to ≤13; moderate disease activity [Mod]: >13 to ≤27; high disease activity [HDA]: >27 [Machado PM. Ann Rheum Dis. 2016;75:787-790]) from BL to Week 52. Mean values of articular and non-articular variables (PASI, SJC/TJC, MASES, dactylitis) from BL to Week 52 were assessed by cDAPSA category achieved at Week 52 to determine the association between achievement of targets and control of articular and non-articular manifestations. Results from the current analyses were compared with the previously reported results from PALACE 1-3.

Results: A total of 175 subjects receiving APR were included; at BL, 66.3% were in HDA, 31.4% in Mod, and 2.3% were in LDA. Overall, subjects who achieved treatment targets (LDA or REM) by Week 52 had lower levels of disease activity at BL, as shown by a lower number of swollen and tender joints and lower presence of enthesitis and dactylitis. Higher prevalence of psoriasis-involved body surface area ≥3% at BL was observed. Subjects in Mod at BL were estimated to be more than twice as likely to achieve REM or LDA at Week 52 vs subjects in HDA at BL; for subjects in LDA at BL, the estimated probability of achieving cDAPSA treatment targets was 100% (Figure). PALACE 4 subjects with LDA and Mod at BL exhibited higher estimated probabilities of achieving treatment targets (100.0% and 61.7%, respectively) than those observed in the DMARD-experienced population of PALACE 1-3 (71.1% and 46.9%). Subjects in PALACE 4 who achieved REM or LDA by Week 52 showed no or mild articular and extra-articular disease activity by Week 52, similar to what was observed in the PALACE 1-3 population (Mease PJ, et al. Arthritis Care Res. 2020 Jan 7. Epub).

Conclusion: DMARD-naive subjects in PALACE 4 who had LDA or Mod at BL had the highest likelihood of achieving treatment targets (cDAPSA REM or LDA) by Week 52 with continued APR treatment. Results from the current probability analyses revealed higher probability rates than those observed in the DMARD-experienced PALACE 1-3 population; control of articular and extra-articular manifestations was observed in the DMARD-naive and DMARD-experienced populations.


Disclosure: P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5; A. Kavanaugh, Eli Lilly and Company, 5; A. Ogdie, AbbVie, 5, Amgen, 2, 5, BMS, 1, Celgene, 1, Corrona, 1, Janssen, 1, Eli Lilly, 1, Novartis, 2, 5, Pfizer, 2, 5, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2, Rheumatology Research Foundation, 2, National Psoriasis Foundation, 2; A. Wells, Abbvie, 1, 2, Eli Lilly & Co., 1, 2; M. Bergman, AbbVie, 5, 8, Amgen, 5, 8, Bristol-Myers Squibb, 5, 8, Genentech/Roche, 5, 8, Gilead, 5, 8, Janssen, 5, 8, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Regeneron, 5, 8, Sanofi, 5, 8, Sandoz, 5, 8, JNJ (parent of Janssen), 1; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 5, Gilead, 5, Galapagos, 5, Celgene, 2, 5, Eli Lilly, 2, 5; F. Behrens, Pfizer, 2, 5, 8, Janssen, 2, 5, 8, Chugai, 2, 5, 8, Celgene, 2, 5, 8, Bionorica, 2, Roche, 2, 5, 8, Abbvie, 5, 8, Sanofi, 5, 8, Lilly, 5, 8, Novartis, 5, 8, Genzyme, 5, 8, Boehringer, 5, 8, MSD, 5, 8, Amgen, 5, 8, UCB, 5, 8, Gilead, 5, 8, Sandoz, 5, 8; S. Richter, Amgen Inc., 1; M. Brunori, Amgen Europe GmbH, 1; L. Teng, Amgen Inc., 1; B. Guerette, Amgen Inc., 1; J. Smolen, AbbVie, 2, 5, 8, AstraZeneca, 2, 5, 8, Eli Lilly, 2, 5, 8, Celgene, 5, 8, Celltrion, 5, 8, Chugai, 5, 8, Gilead, 5, 8, ILTOO, 5, 8, Janssen, 5, 8, Kabi, 5, 8, Novartis-Sandoz, 5, 8, Pfizer Inc, 5, 8, Samsung, 5, 8, Sanofi, 5, 8.

To cite this abstract in AMA style:

Mease P, Kavanaugh A, Ogdie A, Wells A, Bergman M, Gladman D, Behrens F, Richter S, Brunori M, Teng L, Guerette B, Smolen J. Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/probability-of-achieving-low-disease-activity-or-remission-with-apremilast-treatment-among-dmard-naive-subjects-with-active-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/probability-of-achieving-low-disease-activity-or-remission-with-apremilast-treatment-among-dmard-naive-subjects-with-active-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology